Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

IN8bio, Inc. (INAB)

1.62   0.18 (12.5%) 11-25 12:56
Open: 1.48 Pre. Close: 1.44
High: 1.64 Low: 1.46
Volume: 53,147 Market Cap: 40(M)

Technical analysis

as of: 2022-11-25 1:58:00 PM
Stoxline posted a STRONG BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 2.15     One year: 2.49
Support: Support1: 1.38    Support2: 1.14
Resistance: Resistance1: 1.84    Resistance2: 2.13
Pivot: 1.56
Moving Average: MA(5): 1.45     MA(20): 1.66
MA(100): 2.05     MA(250): 2.97
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 14.4     %D(3): 6.5
RSI: RSI(14): 47.9
52-week: High: 7.25  Low: 1.38
Average Vol(K): 3-Month: 128 (K)  10-Days: 26 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ INAB ] has closed below upper band by 39.8%. Bollinger Bands are 32.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.47 - 1.48 1.48 - 1.49
Low: 1.42 - 1.43 1.43 - 1.44
Close: 1.43 - 1.44 1.44 - 1.45

Company Description

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Headline News

Tue, 15 Nov 2022
Christmas brings bad tidings for endangered Guatemalan fir - FRANCE 24 English

Thu, 10 Nov 2022
IN8bio Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress - Yahoo Finance

Fri, 04 Nov 2022
IN8bio, Inc. (INAB) Stock Price Today, Quote & News - Seeking Alpha

Thu, 03 Nov 2022
IN8bio to Present Positive Early Data from Ongoing Phase 1 Study of INB-100 at the 64th American Society of Hematology Annual Meeting - Yahoo Finance

Tue, 01 Nov 2022
Is IN8BIO, Inc. (INAB) Stock About to Get Hot Tuesday? - InvestorsObserver

Wed, 12 Oct 2022
Here's Why We're Watching IN8bio's (NASDAQ:INAB) Cash Burn Situation - Simply Wall St

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 25 (M)
Shares Float 7 (M)
% Held by Insiders 25.7 (%)
% Held by Institutions 9.3 (%)
Shares Short 40 (K)
Shares Short P.Month 51 (K)

Stock Financials

EPS -1.3
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.21
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -38.9
Return on Equity (ttm) -73.2
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.07
Qtrly Earnings Growth 0
Operating Cash Flow -18 (M)
Levered Free Cash Flow -11 (M)

Stock Valuations

PE Ratio -1.26
PEG Ratio 0
Price to Book value 1.33
Price to Sales 0
Price to Cash Flow -2.17

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.